Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, ...

Biotech ETFs offer diversified exposure to multiple biotech stocks, reducing individual investment risk. Top biotech ETFs, like iShares and SPDR S&P, have large assets and low expense ratios.

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

Biotech ETFs have had a banner year, earning some investors returns north of 30 percent since January. I say “some investors” because, it turns out, not all biotech ETFs are created equal. In our 2012 ...

Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market. What Are Smart Beta ...

iShares Biotechnology ETF (NASDAQ:IBB) - $0.0828. Payable Sep 19; for shareholders of record Sep 16; ex-div Sep 16. BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH Biotech Looks ...

Prognostications that the AI bubble is grossly overbought have been increasing. The fact that the Magnificent 7 AI stocks, ...

The SPDR S&P Biotech ETF has an expense ratio of 0.35%, which is typical for ETFs focused on biotech or medical advancements. It's up 25% year-to-date as of Nov. 14, and has delivered a 10.5% average ...